U.S. market Closed. Opens in 17 hours 8 minutes

YMAB | Y-mAbs Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue84.82M65.27M34.90M20.75MN/AN/AN/AN/A
Cost of Revenue11.42M7.57M2.51M2.20M166.00KN/AN/AN/A
Gross Profit73.40M57.70M32.38M18.55M-166.00KN/AN/AN/A
Operating Expenses94.59M152.51M147.82M138.48M83.00M43.23M19.24MN/A
Selling, General & Admin43.72M60.94M54.57M44.78M19.51M8.96M4.94M3.18M
Research & Development50.87M91.57M93.25M93.70M63.49M34.27M14.31M13.86M
Other Operating ExpensesN/AN/A62.01M-2.20MN/A-44.00KN/AN/A
Operating Income-21.19M-94.81M-115.43M-119.94M-83.00M-43.23M-19.24M-17.04M
Other Expenses / Income324.00K-757.00K60.16M598.00K1.98M-44.00K83.00K-18.00K
Before Tax Income-20.87M-95.57M-55.27M-119.34M-81.03M-43.27M-19.16M-17.06M
Income Tax Expenses561.00K757.00K1.07M-994.00K-2.14M-44.00KN/AN/A
Net Income-21.43M-96.33M-56.34M-118.34M-78.89M-43.27M-19.16M-17.06M
Interest ExpensesN/A757.00K1.85M598.00K1.98M-44.00KN/AN/A
Basic Shares Outstanding43.65M43.70M43.18M40.12M35.18M28.77M33.29M33.29M
Diluted Shares Outstanding43.65M43.70M43.18M40.12M35.18M28.77M33.29M33.29M
EBITDA-20.45M-94.81M-115.43M-117.73M-83.00M-43.23M-19.16M-17.04M
EBITDA Margin-24.12%-145.27%-330.78%-567.38%0.00%0.00%0.00%0.00%
EBIT-20.87M-94.81M-53.42M-118.74M-79.05M-43.36M-19.16M-17.06M
EBIT Margin-24.60%-145.27%-153.09%-572.24%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙